VIM and cancer: This can be due to the early disease stage of M0 patients, whose cancer cells may not have yet undergone EMT, and/or to the very advanced disease stage of M1 patients, whose transitioning cancer cells may have undergone full epithelial marker loss and concomitant gain of mesenchymal markers, like vimentin.